BioSpace News Archive

Abbott’s new point-of-care test for the novel coronavirus that causes COVID-19 was approved by the U.S. Food and Drug Administration (FDA) under Emergency Use Authorization (EUA).

New data showed consistent effect of FARXIGA in patients with heart failure with reduced ejection fraction, regardless of background therapy

Edwards Lifesciences Corporation announced it will temporarily pause new enrollments in its active pivotal clinical trials of transcatheter mitral and tricuspid therapies, in response to the urgent COVID-19 response around the globe.

XARELTO® has the potential to be the first anticoagulant in 20 years(i) to show a benefit in these high-risk patients Two major Phase 3 trials have evaluated XARELTO® vascular dose plus aspirin in treating patients with atherosclerotic disease [28-March-2020] RARITAN, N.J. , March 28, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson &

Disaster Management Group, a Florida-based disaster recovery firm, has partnered with software developer Promero to launch an app that will provide scheduling services for COVID-19 testing sites nationwide.

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LogicBio Therapeutics, Inc. between December 3, 2018 and February 10, 2020, inclusive of the important May 18, 2020 lead plaintiff deadline in the case.

Siskinds LLP, Siskinds, Desmeules s.e.n.c.r.l., Rochon Genova LLP, and Merchant Law Group announced court approval of a Canada-wide settlement reached in two class actions related to certain women’s pelvic mesh devices for treatment of Pelvic Organ Prolapse and Stress Urinary Incontinence manufactured and distributed by American Medical Systems Canada Inc. and American Medical Systems, Inc.

Ryvu Therapeutics (WSE: RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation (ODD) to Ryvu’s SEL120, for the treatment of patients with acute myelo

- Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials showed inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months(1) - Prespecified exploratory analysis based on safety reporting from the three trials, showed fewer major adverse cardiovascular events (MACE) with inclisiran compared to placebo(1) - The data are consistent with LDL-C lowering as a strong surrogate for improved patient cardiovascular outcomes(2)

Disaster Management Group, a South Florida-based disaster recovery firm, announced DMGtest, a screening tool for COVID-19 that gives results in 15 minutes.